Prostate Cancer Clinical Trials in Cleveland

Showing 261-280 of 329 trials

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

NCT02349139

This study will be conducted in three parts. Part A is a dose-escalation study to determine two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate cancer. Part A will also characterize the pharmacokinetics and pharmacodynamics of the ASN001 through blood sampling. Subjects in Part B will receive one of two doses identified in Part A to determine which one is more effective, and collect additional pharmacokinetic data. Part C is an extension for subjects completing either Part A or B.

Cancer of the ProstateNeoplasms, ProstateProstate Cancer+3 more

Asana BioSciences27 participantsStarted Jan 2015

Los Angeles, California, United States • Detroit, Michigan, United States • Cleveland, Ohio, United States +3 more locations

COMPLETEDPhase 1< 1 mile

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

NCT02514213

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Prostate Cancer

Inovio Pharmaceuticals62 participantsStarted Jul 2015

Baltimore, Maryland, United States • Detroit, Michigan, United States • Omaha, Nebraska, United States +7 more locations

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Prostate Cancer Trials in Other Cities

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

For Cause Prostate Biopsy in REDUCE Population Trial

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Health-Related Quality of Life in Gay Men With Localized Prostate Cancer

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Other Conditions in Cleveland